TAG:
laboratory company
PAML, Pathology and New Opportunities
By R. Lewis Dark | From the Volume XIX No. 17 – December 10, 2012 Issue
BY ANY MEASURE, MAJOR CHANGES ARE COMING to the profession of laboratory medicine. I assume that you are familiar with most of the trends, healthcare reforms, and significant reductions in lab test reimbursement that appear regularly in the headlines. Many of these developments are unfavorable to th…
Four California Labs Sue Quest and Three Insurers
By Joseph Burns | From the Volume XIX No. 17 – December 10, 2012 Issue
CEO SUMMARY: Allegations of anticompetitive and monopolistic behaviors that violate state and federal laws are the basis of a private lawsuit filed by four independent clinical lab companies in California. The defendants are Quest Diagnostics Incorporated, Aetna, Blue Shield of California…
First-Mover Labs Reveal Success with Lean & QMS
By Robert Michel | From the Volume XIX No. 16 – November 19, 2012 Issue
CEO SUMMARY: There is good news for those clinical labs and pathology groups currently operating robust Lean, Six Sigma, and process improvement programs. The Institute of Medicine’s new report calls for all healthcare providers to rapidly transform themselves into ‘continuously learn…
Ampersand Buys Calloway Labs, Enters Pain Management Market
By Robert Michel | From the Volume XIX No. – October 8, 2012 Issue
URINE DRUG TESTING for pain management may be a challenging business for clinical labs given that compliance officers in the states and in the federal government have successfully pursued lab compliance abuses in this line of business in recent years. Now comes news that private equity firm …
Sonic Healthcare, Bio-Reference Report Financial Performance
By Robert Michel | From the Volume XIX No. 13 – September 17, 2012 Issue
IN RECENT WEEKS, two of the nation’s larger public laboratory companies issued their earnings reports. In both cases, revenue growth was strong, a distinct difference from the recent financial performance of their two largest lab public company competitors. It was on August 21, 2012, when …
Narrower Provider Networks Topic during Quest Conference Call
By Robert Michel | From the Volume XIX No. 12 – August 27, 2012 Issue
SINCE MAY 1, 2012, the nation’s largest clinical laboratory company has had a new CEO, who is Stephen H. Rusckowski. The company’s second quarter conference call provided an opportunity to learn more about how he views Quest Diagnostics Incorporated. Conducted on July 19, the fi…
Damon Laboratories, Mitt Romney, and Politics
By R. Lewis Dark | From the Volume XIX No. 12 – August 27, 2012 Issue
IT IS SELDOM THAT THE CLINICAL LABORATORY INDUSTRY HITS THE RADAR SCREEN during a presidential election. So it is with some interest that I report to you that Mitt Romney recently touted the lessons he learned while serving on the board of Damon Clinical Laboratories, Inc., as useful…
Lab Site Visits in NZ Show Impact of Lab Contracting
By Robert Michel | From the Volume XIX No. 10 – July 16, 2012 Issue
CEO SUMMARY: In some ways, the story of the New Zealand’s health system’s 15-year strategy to reduce the cost of clinical laboratory testing is a cautionary tale for public laboratory companies in the United States. During THE DARK REPORT’S site visit to several private labs in New …
New Lab Company Intends to Buy Outreach Labs
By Joseph Burns | From the Volume XIX No. 9 – June 25, 2012 Issue
CEO SUMMARY: Based in Brentwood, Tennessee, Regional Diagnostic Laboratories (RDX) says it wants to purchase the laboratory outreach programs of nonprofit community hospitals. RDX is a partnership with Warburg Pincus, a New York investment company. It is a credible buyer and has $250 mill…
In Florida, New Law Bans Certain Lab Sales Practices
By Joseph Burns | From the Volume XIX No. 8 – June 4, 2012 Issue
CEO SUMMARY: Florida law has long prohibited clinical laboratories from giving kickbacks and other forms of remuneration to physicians to induce specimen referrals. Specifically, state regulations have prevented labs from placing specimen collectors in physicians’ offices. Despite these…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized